Data Sheet (Cat.No.T12979)

TargetMol

BI-3406

Chemical Properties



CAS No. : 2230836-55-0

Formula: C23H25F3N4O3

Molecular Weight: 462.46

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BI-3406 is an orally active, highly potent and selective between KRAS and Son of Sevenless 1 (SOS1) interaction inhibitor(IC50 : 6 nM),with anticancer activity.
Targets(IC50)	Raf,p38 MAPK,Ras,Kras

Solubility Information

Solubility	DMSO: 122.5 mg/mL (264.89 mM),Sonication is recommended. Ethanol: 100 mg/mL (216.23 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.14 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1623 mL	10.8117 mL	21.6235 mL
5 mM	0.4325 mL	2.1623 mL	4.3247 mL
10 mM	0.2162 mL	1.0812 mL	2.1623 mL
50 mM	0.0432 mL	0.2162 mL	0.4325 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Marco H Hofmann, et al. Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors. December 2019.
Moghadamchargari Z, Shirzadeh M, Liu C, et al. Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants. Proceedings of the National Academy of Sciences. 2021, 118(12)
Michael Gmachl, et al. Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors. WO2018115380A1.